Phrontline Biopharma, a China-based, clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), announced on Sunday that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company's lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology.

The company says that the Phase 1 study of TJ101 will evaluate its safety, tolerability, pharmacokinetics, and preliminary antitumor activity across multiple solid tumour types. The study design includes dose escalation followed by expansion cohorts to further assess TJ101's potential in a broad patient population.

Phrontline's pipeline includes multiple early-stage ADC assets targeting high-value tumour antigens. The company's dual payload platform leverages a modular design with optimised linker stability and distinct mechanisms of action, enabling improved tumour penetration and a stronger bystander effect.

;;;